Publication | Open Access

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

UrologyMedicinePharmacologyResistance Mutation (Virology)PharmacotherapyFirst-line AbirateroneCastration-resistant Prostate CancerProstatic DiseaseCancer GeneticsAnti-cancer AgentOncologyEndocrine-related Cancer